Angiopoietin-2 promotes ER+ breast cancer cell survival in bone marrow niche

Hyun Ho Han, Baek Gil Kim, Joo Hyun Lee, Suki Kang, Ji Eun Kim, Nam Hoon Cho

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In estrogen receptor-positive (ER+) breast cancer, it is recognized that metastases may develop after a long period of dormancy. Bone marrow (BM) vascular niche is where the dormant tumor cells are most likely to reside. So far, it is not fully understood why the dormant tumor cells become proliferative and eventually generate tumor. We hypothesized that therapeutic or menopause-related estrogen depletion may be the switch behind dormant ER+ tumor cell awakening in BM. We utilized an existing experimental model of BM endothelial niche that can simulate ER+ tumor cell dormancy to test our hypothesis. In results, estrogen depletion paradoxically promoted ER+ tumor cell proliferation in the BM endothelial niche, and their molecular phenotype shifted from dormant to awaken. Following estrogen depletion, the BM niche cells produced angiopoietin-2 (ANGPT2), which destabilized niche endothelium by interfering ANGPT1/Tie2 signaling, and promoted ER+ tumor cell survival under estrogen deficiency via cell surface integrin β1. Knockdown of ANGPT2 completely negated ER+ tumor cell awakening in the niche. Furthermore, ANGPT2 expression in ER+ tumor human samples was associated with increased risk of distant metastasis only in those who underwent adjuvant estrogen depletion therapy, not in those who did not undergo adjuvant therapy. In conclusion, we demonstrate that ANGPT2 signaling activated after estrogen depletion paradoxically triggers ER+ tumor cell awakening from dormancy in their BM niche, partly indirectly via endothelial Tie2 receptor and partly directly via tumor cell surface integrin β1.

Original languageEnglish
Pages (from-to)609-623
Number of pages15
JournalEndocrine-Related Cancer
Volume23
Issue number8
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Angiopoietin-2
Cell Survival
Bone Marrow
Breast Neoplasms
Estrogens
Neoplasms
Integrins
TIE-2 Receptor
Neoplasm Metastasis
Menopause
Bone Marrow Cells
Estrogen Receptors
Endothelium
Blood Vessels
Theoretical Models
Therapeutics

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research

Cite this

Han, Hyun Ho ; Kim, Baek Gil ; Lee, Joo Hyun ; Kang, Suki ; Kim, Ji Eun ; Cho, Nam Hoon. / Angiopoietin-2 promotes ER+ breast cancer cell survival in bone marrow niche. In: Endocrine-Related Cancer. 2016 ; Vol. 23, No. 8. pp. 609-623.
@article{34523f1138da40dfa8a59de08e5db59f,
title = "Angiopoietin-2 promotes ER+ breast cancer cell survival in bone marrow niche",
abstract = "In estrogen receptor-positive (ER+) breast cancer, it is recognized that metastases may develop after a long period of dormancy. Bone marrow (BM) vascular niche is where the dormant tumor cells are most likely to reside. So far, it is not fully understood why the dormant tumor cells become proliferative and eventually generate tumor. We hypothesized that therapeutic or menopause-related estrogen depletion may be the switch behind dormant ER+ tumor cell awakening in BM. We utilized an existing experimental model of BM endothelial niche that can simulate ER+ tumor cell dormancy to test our hypothesis. In results, estrogen depletion paradoxically promoted ER+ tumor cell proliferation in the BM endothelial niche, and their molecular phenotype shifted from dormant to awaken. Following estrogen depletion, the BM niche cells produced angiopoietin-2 (ANGPT2), which destabilized niche endothelium by interfering ANGPT1/Tie2 signaling, and promoted ER+ tumor cell survival under estrogen deficiency via cell surface integrin β1. Knockdown of ANGPT2 completely negated ER+ tumor cell awakening in the niche. Furthermore, ANGPT2 expression in ER+ tumor human samples was associated with increased risk of distant metastasis only in those who underwent adjuvant estrogen depletion therapy, not in those who did not undergo adjuvant therapy. In conclusion, we demonstrate that ANGPT2 signaling activated after estrogen depletion paradoxically triggers ER+ tumor cell awakening from dormancy in their BM niche, partly indirectly via endothelial Tie2 receptor and partly directly via tumor cell surface integrin β1.",
author = "Han, {Hyun Ho} and Kim, {Baek Gil} and Lee, {Joo Hyun} and Suki Kang and Kim, {Ji Eun} and Cho, {Nam Hoon}",
year = "2016",
month = "1",
day = "1",
doi = "10.1530/ERC-16-0086",
language = "English",
volume = "23",
pages = "609--623",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "Society for Endocrinology",
number = "8",

}

Angiopoietin-2 promotes ER+ breast cancer cell survival in bone marrow niche. / Han, Hyun Ho; Kim, Baek Gil; Lee, Joo Hyun; Kang, Suki; Kim, Ji Eun; Cho, Nam Hoon.

In: Endocrine-Related Cancer, Vol. 23, No. 8, 01.01.2016, p. 609-623.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Angiopoietin-2 promotes ER+ breast cancer cell survival in bone marrow niche

AU - Han, Hyun Ho

AU - Kim, Baek Gil

AU - Lee, Joo Hyun

AU - Kang, Suki

AU - Kim, Ji Eun

AU - Cho, Nam Hoon

PY - 2016/1/1

Y1 - 2016/1/1

N2 - In estrogen receptor-positive (ER+) breast cancer, it is recognized that metastases may develop after a long period of dormancy. Bone marrow (BM) vascular niche is where the dormant tumor cells are most likely to reside. So far, it is not fully understood why the dormant tumor cells become proliferative and eventually generate tumor. We hypothesized that therapeutic or menopause-related estrogen depletion may be the switch behind dormant ER+ tumor cell awakening in BM. We utilized an existing experimental model of BM endothelial niche that can simulate ER+ tumor cell dormancy to test our hypothesis. In results, estrogen depletion paradoxically promoted ER+ tumor cell proliferation in the BM endothelial niche, and their molecular phenotype shifted from dormant to awaken. Following estrogen depletion, the BM niche cells produced angiopoietin-2 (ANGPT2), which destabilized niche endothelium by interfering ANGPT1/Tie2 signaling, and promoted ER+ tumor cell survival under estrogen deficiency via cell surface integrin β1. Knockdown of ANGPT2 completely negated ER+ tumor cell awakening in the niche. Furthermore, ANGPT2 expression in ER+ tumor human samples was associated with increased risk of distant metastasis only in those who underwent adjuvant estrogen depletion therapy, not in those who did not undergo adjuvant therapy. In conclusion, we demonstrate that ANGPT2 signaling activated after estrogen depletion paradoxically triggers ER+ tumor cell awakening from dormancy in their BM niche, partly indirectly via endothelial Tie2 receptor and partly directly via tumor cell surface integrin β1.

AB - In estrogen receptor-positive (ER+) breast cancer, it is recognized that metastases may develop after a long period of dormancy. Bone marrow (BM) vascular niche is where the dormant tumor cells are most likely to reside. So far, it is not fully understood why the dormant tumor cells become proliferative and eventually generate tumor. We hypothesized that therapeutic or menopause-related estrogen depletion may be the switch behind dormant ER+ tumor cell awakening in BM. We utilized an existing experimental model of BM endothelial niche that can simulate ER+ tumor cell dormancy to test our hypothesis. In results, estrogen depletion paradoxically promoted ER+ tumor cell proliferation in the BM endothelial niche, and their molecular phenotype shifted from dormant to awaken. Following estrogen depletion, the BM niche cells produced angiopoietin-2 (ANGPT2), which destabilized niche endothelium by interfering ANGPT1/Tie2 signaling, and promoted ER+ tumor cell survival under estrogen deficiency via cell surface integrin β1. Knockdown of ANGPT2 completely negated ER+ tumor cell awakening in the niche. Furthermore, ANGPT2 expression in ER+ tumor human samples was associated with increased risk of distant metastasis only in those who underwent adjuvant estrogen depletion therapy, not in those who did not undergo adjuvant therapy. In conclusion, we demonstrate that ANGPT2 signaling activated after estrogen depletion paradoxically triggers ER+ tumor cell awakening from dormancy in their BM niche, partly indirectly via endothelial Tie2 receptor and partly directly via tumor cell surface integrin β1.

UR - http://www.scopus.com/inward/record.url?scp=84989332426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989332426&partnerID=8YFLogxK

U2 - 10.1530/ERC-16-0086

DO - 10.1530/ERC-16-0086

M3 - Article

C2 - 27353038

AN - SCOPUS:84989332426

VL - 23

SP - 609

EP - 623

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 8

ER -